Meta‐analysis of clinical trials as a scientific discipline. I: Control of bias and comparison with large co‐operative trials

Statistics in Medicine

Volumn 6, Issue 3, 1987, Pages 315-325

  Chalmers, Thomas C ^a   Levin, Howard ^a   Sacks, Henry S ^a   Reitman, Dinah ^a   Berrier, Jayne ^a   Nagalingam, Raguraman ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Co operative trials; Double blind method; Meta analysis; Random allocation bias; Randomized control trials

Indexed keywords

BIAS; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EPIDEMIOLOGY; META ANALYSIS; NONBIOLOGICAL MODEL;

ADRENERGIC BETA-ANTAGONISTS; CEREBRAL HEMORRHAGE; CLINICAL TRIALS; DATA COLLECTION; DOUBLE-BLIND METHOD; HUMANS; INFANT, NEWBORN; MYOCARDIAL INFARCTION; PHENOBARBITAL; PUBLISHING; RANDOM ALLOCATION; STREPTOKINASE;

EID: 0023260901     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4780060320     Document Type: Article

References (81)

1. Primary, secondary and meta‐analysis of research
2. Findings for public health from meta‐analysis
3. Why do we need some large, simple randomized trials
4. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design
5. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
6. A method for assessing the quality of a randomized control trial
7. Reporting standards and research strategies for controlled trials: agenda for the editor
8. Meta‐analyses of randomized control trials
9. Meta‐analyses of randomized control trials
10. The control of bias in clinical trials
11. Bias in treatment assignment in controlled clinical trials
12. Loss of patients in clinical trials that measure long‐term survival following myocardial infarction
13. A quality assessment of randomized control trials of primary treatment of breast cancer
14. An approach to overviews
15. Avoidance of large biases in the assessment of moderate treatment effects: the need for systematic overviews
16. Obtaining medically meaningful answers from an overview of randomized clinical trials
17. The epidemiology of unpublished randomized control trials
18. Nonassociation of adrenocorticosteroid therapy and peptic ulcer
19. Association of adrenocorticosteroid therapy and peptic‐ulcer disease
20. Aspects of the natural history of gastrointestinal bleeding in cirrhosis and the effect of prednisone
21. A note on fatality in serum hepatitis
22. The importance of negative results in psychological research
23. The “file drawer problem” and tolerance for null results
24. A measure to aid in the interpretation of publicised clinical trials
25. Comparison of MEDLINE searching with a perinatal clinical trials database
26. Reduction of infarct size with the early use of timolol in acute myocardial infarction
27. Reduction of infarct size by the early use of intravenous timolol in acute myocardial infarction
28. Effect of timolol on changes in serum potassium concentration during acute myocardial infarction
29. Reduction in infarct size, arrhythmias and chest pain by early intravenous beta blockade in suspected acute myocardial infarction
30. Reduction of ventricular arrhythmias by early intravenous atenolol in suspected acute myocardial infarction
31. Early intravenous beta‐blockade in myocardial infarction
32. Early intravenous atenolol treatment in suspected acute myocardial infarction. Preliminary report of a randomised trial
33. Reduction of enzyme by propranolol after actue myocardial infarction
34. Treatment of acute myocardial infarction with propranolol. Further studies on enzyme appearance and subsequent left ventricular function in treated and control patients with developing infarcts
35. Beta‐adrenergic blockade and cardiac arrhythmias
36. Propranolol decreases sympathetic nervous activity reflected by plasma catecholamines during evolution of myocardial infarction in man
37. Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol
38. The Goteborg metoprolol trial in acute myocardial infarction
39. Effect of alprenolol on mortality among patients with definite or suspected acute myocardial infarction. Preliminary Results
40. Limitation of myocardial infarct size in patients less than 66 years treated with alprenolol
41. Effect of acute and long‐term beta‐adrenergic blockade with alprenolol in definite or suspected myocardial infarction
42. Protective effect of propranolol in threatened myocardial infarction
43. Intravenous and oral practolol in the acute stages of myocardial infarction
44. Very early intervention with metoprolol in suspected acute myocardial infarction
45. Beta blockade during and after myocardial infarction: An overview of the randomized trials
46. MIAMI: Metoprolol in acute myocardial infarction
47. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS‐1
48. Streptokinase in recent myocardial infarction: A controlled multicentre trial
49. Fibrinolytic treatment in acute myocardial infarction
50. Controlled trial of streptokinase and heparin in acute myocardial infarction
51. Australian mutlicentre trial of streptokinase in acute myocardial infarction
52. Streptokinase in acute myocardial infarction: a controlled multicentre study in the United Kingdom
53. European Cooperative Study Group for Streptokinase Treatment in Acute Myocardial Infarction
54. Streptokinase in Acute myocardial infarction extended report of the European cooperative trial
55. Single‐blind randomised multicentre trial comparing heparin and streptokinase treatment in recent myocardial infarction
56. A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.)
57. A randomized controlled trial of intravenous streptokinase in evolving acute myocardial infarction
58. Fibrinolytic therapy in acute myocardial infarction
59. Biochemical evaluation of standard treatment with streptokinase in acute myocardial infarction
60. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
61. Phenobartitone prophylaxis of intraventricular haemorrhage
62. Effect of prophylactic phenobarbital on intraventricular hemorrhage in high‐risk infants
63. Phenobarbitone for prevention of periventricular haemorrhage in very low birth‐weight infants. A randomised double‐blind trial
64. Further Observations on the use of phenobarbital to prevent neonatal intracranial hemorrhage
65. Phenobarbitone and neonatal intraventricular haemorrhage
66. Prevention of intraventricular haemorrhage in preterm infants by phenobarbitone. A controlled trial
67. Does phenobarbitone prevent periventricular hemorrhage in very low‐birth‐weight babies?: A controlled trial
68. Failure of phenobarbitone to prevent neonatal intraventricular haemorrhage
69. Phenobarbitone to prevent intraventricular haemorrhage
70. Brain protection by phenobarbitone in very low birthweight (VLBW) prematures‐a controlled trial
71. Effect of phenobarbital on motor activity and intraventricular hemorrhage in preterm infants with respiratory disease weighing less than 1500 grams
72. Neonatal intracranial hemorrhage and phenobarbital
73. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: Overview of results on mortality, reinfarction and side‐effects from 33 randomized controlled trials
74. Effect of intravenous streptokinase on acute myocardial infarction